Weekly Analysts’ Ratings Updates for TransMedics Group (TMDX)

Several analysts have recently updated their ratings and price targets for TransMedics Group (NASDAQ: TMDX):

• 5/9/2026 – TransMedics Group was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/6/2026 – TransMedics Group had its price target lowered by Canaccord Genuity Group Inc. from $152.00 to $124.00. They now have a “buy” rating on the stock.
• 5/6/2026 – TransMedics Group had its price target lowered by TD Cowen from $190.00 to $120.00. They now have a “buy” rating on the stock.
• 5/6/2026 – TransMedics Group had its price target lowered by Stifel Nicolaus from $130.00 to $85.00. They now have a “hold” rating on the stock.
• 5/6/2026 – TransMedics Group had its price target lowered by Piper Sandler from $160.00 to $120.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – TransMedics Group had its price target lowered by Needham & Company LLC from $174.00 to $142.00. They now have a “buy” rating on the stock.
• 5/6/2026 – TransMedics Group was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
• 3/16/2026 – TransMedics Group had its “buy” rating reaffirmed by TD Cowen.

Insider Activity at TransMedics Group

In other news, Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total transaction of $178,496.66. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $428,810.92. The trade was a 29.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the transaction, the chief financial officer owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. This trade represents a 33.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 16,205 shares of company stock valued at $2,353,002. 6.90% of the stock is owned by corporate insiders.

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.